Business Wire

FAIRBRICS

17.1.2023 08:01:39 CET | Business Wire | Press release

Share
Fairbrics Raises €22 M to Bring to Market its CO2-Based Polyester Fiber and Reduce the Textile Industry’s Carbon Footprint

Faibrics, a sustainable chemical company developing a technology that converts CO2 emissions into high value polyester through a circular manufacturing approach, announced today it has raised €17 M from the European Union’s Horizon 2020 Research & Innovation Program and 5 M€ from Partners to the Technology Upscaling Project, representing a total amount of €22 M to bring its innovative solution to market.

The EU’s grant was awarded to a consortium coordinated by Fairbrics that brings together 13 partners from 7 countries throughout Europe, ranging from upstream and process development experts (i.e. engineering design, CO2 capture, chemical reuse, electrolyzer) to final product specialists (i.e. Faurecia for automotive, Les Tissages de Charlieu for textile). To prompt societal impact, the Project also includes a strong educational component and, together with academic partners, it will develop learning and training resources on CO2 valorization for young professionals, university students and lifelong learners.

The combined funds will be used to upscale Fairbrics’ technology, first in a pilot line of 100 kg/day by 2024 and later, by 2026, in a 1 ton/day demo plant. The primary aim is to fight climate change and accelerate energy intensive industries’ decarbonation by replacing fossil-based polyester with CO2-based polyester, using a circular approach that recycles CO2 waste fumes from chemical plants into high value textile products. Fairbrics targets sectors employing polyester as a main material: clothing but also sports equipment, automotive and packaging.

“By using CO2 emissions instead of fossil resources to manufacture polyester, Fairbrics addresses one of the greatest global challenge, climate change caused greenhouse gas (GHG) emission. This funding comes as a strong recognition of the work Fairbrics has accomplished so far, the quality of the consortium we brought together, and the extraordinary potential of our technology to provide highly polluting industries like textile with an alternate environment-friendly and economically viable solution,” said Benoît Illy, Cofounder and CEO of Fairbrics.

Today, polyester accounts for 60% of all textiles produced worldwide and a third of the fashion industry’s GHG emission. By replacing fossil fuel sources by CO2-based sources, Fairbrics provides a sustainable and scalable solution to energy intensive industries. Fairbrics will initially address the fashion industry and has already secured strategic partnerships with major brands such as H&M, On-Running and Aigle. It intends to progressively diversify its technology platform with solutions addressing other sectors such as sports equipment, packaging and automotive.

About Fairbrics
Fairbrics is sustainable chemical company founded in 2019 and based in Paris (France). It has developed a disruptive patented technology platform that converts CO2 emissions into high value polyester fibers, providing energy intensive industries with environment-friendly and economically viable solutions. Fairbrics’ mission is to fight climate change by developing circular manufacturing process. Its technology has been demonstrated at lab-scale. Fairbrics has successfully secured partnerships with major fashion brands such as H&M, On-Running and Aigle. Next to clothing, the company intends to progressively deploy its technology to address other industries that employ polyester as their main material such as automotive and packaging. Fairbrics won several national and international innovation awards: Citeo Circular Challenge, French Tech Green20, I-Nov, Cleantech Open France, H&M Foundation’s Global Challenge Award. For more information: www.fairbrics.co

Partners to Fairbrics’ Technology Upscaling Project
Next to Fairbrics, participants to the Technology Upscaling Project include The University of Antwerp (Belgium), TECNALIA (Spain), Lappeenrannan Lahden teknillinen yliopisto (Finland), AIMPLAS (Spain), CiaoTech (Italy), Deutsche institute fur textil- und faserforschung denkendorf (Germany), CITY OF LAPPEENRANTA VILLMANSTRAND (Finland), DIGIOTOUCH OU (Estonia), Faurecia (France), Naldeo (France), SurePure (Belgium), Les Tissages de Charlieu (France).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005284/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EVE Energy Strengthens European Operations Through Compliance, Local Manufacturing, and Regional Services2.7.2026 08:30:00 CEST | Press release

The Smarter E Europe 2026 opened in Munich on June 23 and runs through June 25, gathering global players from the clean energy sector on one of Europe’s most influential trade exhibition platforms. EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, all-scenario storage solutions, and high-performance EV batteries — showcasing its lithium-sodium dual-technology platform, full product portfolio, and localized European operational layout. During the exhibition, European clients showed strong interest in the company’s product performance and placed strong emphasis on sustained adherence to the EU’s evolving regulatory standards. This industry attitude further underscores that regulatory compliance readiness has become a fundamental prerequisite for accessing the European clean energy market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701651416/en/ The BMW iX3 displayed at the EVE Energy booth

Braun Launches the Next Generation of Electric Shaver With Braun NEVO Introducing a New Dawn of Smooth Touch2.7.2026 08:00:00 CEST | Press release

With over 100 years of exceptional German craftsmanship, Braun introduces Braun NEVO, an electric shaver redefining what a close shave and smooth skin mean. Every element has been reimagined: the sleek unibody stainless steel handle, the revolutionary AeroTouch™ Technology and advanced personalized display deliver a perfectly close shave without sacrificing comfort. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701842080/en/ Braun NEVO Shaver Oliver Grabes, Braun Head of Design, said: “At Braun, we set out to reimagine the shaving experience which led to the development of AeroTouch™ Shaving Technology, a cutting system engineered for ultra-low friction on the skin and high efficiency. This makes Braun NEVO our best shaver* setting a new standard for smooth skin.” Introducing the revolutionary world’s first AeroTouch™ Technology, featuring 250 diamond-sharp cutting edges and an exclusive Ultra gliding foil for a smooth g

Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member2.7.2026 08:00:00 CEST | Press release

Brenus Pharma, today announced key appointments to its board of directors. The company welcomes Eric DESSERTENNE, as President & Chairman of the board, succeeding co-founder Jacques GARDETTE, who will remain an active board member. Eric brings extensive experience in healthcare innovation and value creation, having notably led BIOCORP through its development and acquisition by Novo Nordisk. Brenus also appoints Camilla SYLVEST, as a second independent director, following the earlier addition of Diala EZZEDDINE a seasoned US-based biotech executive and entrepreneur. Camilla SYLVEST is an experienced pharmaceutical executive and global business leader, having spent nearly three decades at Novo Nordisk A/S, where she most recently served as Executive Vice President for Global Commercial Strategy, Corporate Communication and Sustainability. She currently serves on the Boards of Argenx SE, Getinge AB, and Zealand Pharma A/S, and has previously served on the Board of Danish Crown A/S and as

Access Advance and Alibaba Announce Alibaba's Expanded Participation in the VDP Pool2.7.2026 02:00:00 CEST | Press release

Access Advance LLC and Alibaba Group today announced that Alibaba has joined the Access Advance Video Distribution Patent Pool (VDP Pool) as a Licensee, securing a license to the pool's comprehensive coverage of HEVC, VVC, VP9, and AV1 codec technologies. The announcement marks a milestone in a multi-year collaboration between the two companies that spans the VVC Advance Patent Pool, where Alibaba participates as both a Licensor and Licensee, and the VDP Pool, where Alibaba joined as a Licensor in 2025. Alibaba's subsidiary Youku, one of China's leading streaming platforms, also joined the VDP Pool as a Licensee in 2025. Alibaba operates one of the world's most diverse video ecosystems, spanning a wide range of video-based services across e-commerce, entertainment, and digital media. As video has become central to how consumers shop, communicate, and access entertainment, the breadth of Alibaba's video operations reflects the kind of business model complexity the VDP Pool was designed

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia2.7.2026 01:58:00 CEST | Press release

- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia -- Approximately 5,500 additional children in the U.S. are now eligible for this established one-time therapy, expanding upon the prior FDA approval in people 12 years and older -- Regulatory review for label expansion underway in the Kingdom of Saudi Arabia and United Kingdom - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY® (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT. “Just as we redefined what is possible in cystic fibrosis, our ambition is to transform

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye